A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

Also called NCT02877173

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Guangzhou Yipinhong Pharmaceutical CO.,LTD (from the registry)
Registry
  • NCT NCT02877173
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02877173. Randomized; double masking; primary purpose treatment. Start 2016-08 (registry gives no type); primary completion 2017-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
Condition
Arteriosclerosis Obliterans
Intervention (Drug)
Alprostadil Liposomes for Injection
Intervention (Drug)
Alprostadil Injection
Lead sponsor
Guangzhou Yipinhong Pharmaceutical CO.,LTD (class: industry)

Record details

Record id
cardio:ct-nct02877173
Content hash
b15bb906a79f8e41d9ac953dcb31d25c96cd9a2d1bca5079af52e617a7fb8490